Mandate

Vinge represents Symrise in connection with its mandatory offer on Probi

February 06, 2014

Symrise AG has, after having acquired shares corresponding to approximately 30.03 per cent of the votes in Probi AB (publ), launched a mandatory offer to the shareholders in Probi, with an offered price of SEK 40.10 per share. Vinge represents Symrise in connection with the mandatory offer.

Symrise is a global supplier of fragrances, flavourings, cosmetic, active ingredients, and raw materials as well as functional ingredients. The company’s share is listed on the Frankfurt Stock Exchange and the market capitalisation of Symrise is EUR 4 billion.

Probi is a research-driven biotechnology company focused on the global probiotics market. Through Probi’s research Probi has developed probiotics with well-documented beneficial health effects. The company’s share is listed on NASDAQ OMX Stockholm, Small cap and the market capitalisation of Probi is approximately MSEK 375.

Vinge’s team primarily consists of Jesper Schönbeck, Oskar Belani, Joakim Hagberg and Sabina Börjesson.

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025